Group items tagged

Patients with advanced non-small cell lung cancer may have tumour biopsy replaced with a simple blood test to assess their treatment options.

Final results from the Phase III FLAURA trial investigating AstraZeneca's Tagrissofinal reinforce the therapy as the SOC for first-line treatment of patients with EGFRm advanced NSCLC.

Roche's Tecentriq: Results demonstrated that first-line treatment of patients with advanced non-small cell lung cancer and high programmed cell death ligand-1 expression who used Roche's Tecentriq monotherapy resulted in improved overall survival compared with platinum-based chemotherapies.